Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addiction Medicine
FDA approves Campral Delayed-Release Tablets for treating alcohol dependence
September 5th, 2004
Forest Laboratories, Inc., (FRX) and Merck, KGaA, (Merck) of Darmstadt, Germany, announced the United States Food and Drug Administration (FDA) has approved Campral (acamprosate calcium) Delayed-Release Tablets for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with Campral should be part of a comprehensive management program that includes psychosocial support. Forest expects Campral to be available to physicians, patients, and pharmacies around the end of the year. Developed by Merck, Campral is the first new medication in 9 years to be approved in the U.S. for the...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
